PriceTargets.com logo

Inspire Medical Systems - INSP Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $233.58
  • Forecasted Upside: 24.40%
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$187.77 As of 12/20/2024 06:16 PM ET
▲ +2.35 (1.27%)

This chart shows the closing price for INSP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Inspire Medical Systems Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INSP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INSP

Analyst Price Target is $233.58
▲ +24.40% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Inspire Medical Systems in the last 3 months. The average price target is $233.58, with a high forecast of $260.00 and a low forecast of $197.00. The average price target represents a 24.40% upside from the last price of $187.77.

This chart shows the closing price for INSP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 12 polled investment analysts is to moderate buy stock in Inspire Medical Systems. This rating has held steady since September 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/20/2024Bank of AmericaUpgradeNeutral ➝ Buy$220.00 ➝ $255.00
11/5/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$260.00 ➝ $260.00
11/5/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$255.00 ➝ $260.00
11/5/2024Stifel NicolausReiterated RatingHold ➝ Hold$170.00 ➝ $200.00
11/5/2024Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$187.00 ➝ $198.00
11/5/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$240.00 ➝ $252.00
9/30/2024Truist FinancialReiterated RatingBuy ➝ Buy$217.00 ➝ $240.00
9/10/2024Leerink PartnersBoost TargetMarket Perform ➝ Market Perform$167.00 ➝ $197.00
8/7/2024KeyCorpLower TargetOverweight ➝ Overweight$278.00 ➝ $236.00
8/7/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$260.00 ➝ $260.00
8/7/2024Robert W. BairdLower TargetOutperform ➝ Outperform$220.00 ➝ $200.00
7/16/2024Truist FinancialLower TargetBuy ➝ Buy$280.00 ➝ $217.00
7/15/2024Morgan StanleyLower TargetOverweight ➝ Overweight$250.00 ➝ $210.00
6/24/2024Stifel NicolausLower TargetHold ➝ Hold$210.00 ➝ $170.00
6/3/2024Bank of AmericaLower TargetNeutral ➝ Neutral$225.00 ➝ $185.00
5/8/2024Piper SandlerBoost TargetOverweight ➝ Overweight$250.00 ➝ $255.00
5/8/2024Bank of AmericaDowngradeBuy ➝ Neutral$265.00 ➝ $225.00
4/19/2024Royal Bank of CanadaInitiated CoverageOutperform$285.00
3/27/2024MizuhoReiterated RatingBuy ➝ Buy$250.00
3/20/2024Truist FinancialReiterated RatingBuy ➝ Buy$280.00
3/19/2024Morgan StanleyInitiated CoverageOverweight$250.00
2/7/2024Truist FinancialBoost TargetBuy ➝ Buy$265.00 ➝ $280.00
2/7/2024MizuhoBoost TargetBuy ➝ Buy$225.00 ➝ $250.00
2/6/2024KeyCorpInitiated CoverageOverweight$278.00
1/19/2024Jefferies Financial GroupInitiated CoverageBuy$245.00
1/2/2024Stifel NicolausReiterated RatingBuy ➝ Hold$210.00
12/22/2023Truist FinancialBoost TargetBuy ➝ Buy$240.00 ➝ $260.00
12/13/2023Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$245.00 ➝ $187.00
11/8/2023MizuhoLower TargetBuy ➝ Buy$300.00 ➝ $215.00
11/8/2023Truist FinancialLower TargetBuy ➝ Buy$260.00 ➝ $240.00
11/8/2023Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$330.00 ➝ $245.00
11/7/2023Stifel NicolausLower TargetBuy ➝ Buy$350.00 ➝ $250.00
10/17/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$340.00 ➝ $181.00
10/16/2023Leerink PartnrsReiterated RatingMarket Perform
10/16/2023Leerink PartnersInitiated CoverageMarket Perform$159.00
10/2/2023Truist FinancialReiterated RatingBuy ➝ Buy$340.00
9/6/2023UBS GroupLower TargetBuy ➝ Buy$405.00 ➝ $322.00
8/24/2023Truist FinancialLower TargetBuy ➝ Buy$363.00 ➝ $340.00
8/2/2023Truist FinancialLower TargetBuy ➝ Buy$380.00 ➝ $363.00
8/2/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$300.00 ➝ $340.00
8/2/2023Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$315.00 ➝ $330.00
8/2/2023Lake Street CapitalBoost TargetBuy ➝ Buy$305.00 ➝ $350.00
8/2/2023UBS GroupBoost Target$395.00 ➝ $405.00
7/19/2023Truist FinancialBoost Target$360.00 ➝ $380.00
7/18/2023Robert W. BairdInitiated CoverageOutperform$371.00
7/18/2023Piper SandlerBoost Target$340.00 ➝ $360.00
7/17/2023MizuhoBoost Target$300.00 ➝ $380.00
7/13/2023Stifel NicolausBoost Target$300.00 ➝ $350.00
7/4/2023Bank of AmericaBoost Target$310.00 ➝ $355.00
6/8/2023Piper SandlerBoost Target$315.00 ➝ $340.00
6/8/2023KeyCorpBoost Target$321.00 ➝ $335.00
5/18/2023Truist FinancialBoost Target$335.00 ➝ $360.00
5/3/2023Piper SandlerBoost Target$305.00 ➝ $315.00
5/3/2023UBS GroupBoost Target$300.00 ➝ $304.00
5/3/2023KeyCorpBoost Target$303.00 ➝ $321.00
4/13/2023MizuhoInitiated CoverageBuy$300.00
4/11/2023Stifel NicolausBoost TargetBuy$290.00 ➝ $300.00
3/28/2023UBS GroupInitiated CoverageBuy$300.00
2/8/2023Lake Street CapitalBoost Target$250.00 ➝ $305.00
2/8/2023JPMorgan Chase & Co.Boost TargetOverweight$271.00 ➝ $300.00
2/8/2023Truist FinancialBoost TargetBuy$310.00 ➝ $330.00
2/8/2023Piper SandlerBoost TargetOverweight$300.00 ➝ $305.00
1/31/2023Truist FinancialBoost TargetBuy$308.00 ➝ $310.00
1/26/2023Piper SandlerBoost TargetOverweight$285.00 ➝ $300.00
1/13/2023KeyCorpBoost TargetOverweight$287.00 ➝ $303.00
12/20/2022Truist FinancialBoost TargetBuy$270.00 ➝ $308.00
12/13/2022The Goldman Sachs GroupUpgradeNeutral ➝ Buy$245.00 ➝ $308.00
12/13/2022KeyCorpInitiated CoverageOverweight$287.00
11/2/2022Lake Street CapitalLower Target$320.00 ➝ $250.00
10/17/2022Truist FinancialLower TargetBuy$280.00 ➝ $240.00
8/3/2022Piper SandlerLower TargetOverweight$310.00 ➝ $285.00
6/10/2022Truist FinancialLower TargetBuy$296.00 ➝ $250.00
5/4/2022Piper SandlerBoost Target$305.00 ➝ $310.00
4/12/2022Truist FinancialInitiated CoverageBuy$315.00
4/5/2022Wolfe ResearchInitiated CoverageMarket Perform$270.00
3/2/2022Bank of AmericaInitiated CoverageBuy ➝ Buy
2/9/2022Leerink PartnersBoost TargetOutperform$270.00 ➝ $273.00
11/3/2021Lake Street CapitalBoost TargetBuy$260.00 ➝ $320.00
11/3/2021Wells Fargo & CompanyBoost TargetOverweight$250.00 ➝ $305.00
11/3/2021Leerink PartnersBoost TargetOutperform$300.00 ➝ $325.00
11/3/2021Piper SandlerBoost TargetPositive ➝ Overweight$238.00 ➝ $305.00
10/22/2021Leerink PartnersReiterated RatingOutperform
9/24/2021Leerink PartnersBoost TargetOutperform$265.00 ➝ $300.00
8/4/2021Leerink PartnersLower TargetOutperform$275.00 ➝ $265.00
8/4/2021Piper SandlerBoost TargetOverweight$215.00 ➝ $238.00
7/20/2021Piper SandlerLower TargetOverweight$235.00 ➝ $215.00
7/14/2021Piper SandlerLower TargetOverweight ➝ Overweight$255.00 ➝ $235.00
6/23/2021Leerink PartnersReiterated RatingBuy
5/25/2021Leerink PartnersReiterated RatingBuy
5/5/2021Lake Street CapitalBoost TargetBuy$250.00 ➝ $260.00
5/5/2021Piper SandlerBoost TargetPositive ➝ Overweight$252.00 ➝ $255.00
4/25/2021Robert W. BairdReiterated RatingBuy
2/24/2021Piper SandlerBoost TargetOverweight$210.00 ➝ $252.00
2/24/2021Lake Street CapitalBoost TargetBuy$215.00 ➝ $250.00
2/24/2021Leerink PartnersBoost TargetOutperform$225.00 ➝ $275.00
1/7/2021Lake Street CapitalBoost TargetBuy$150.00 ➝ $215.00
1/4/2021Bank of AmericaDowngradeBuy ➝ Neutral
12/15/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$162.00 ➝ $209.00
12/3/2020Piper SandlerBoost TargetOverweight$147.00 ➝ $210.00
11/3/2020Wells Fargo & CompanyBoost TargetOverweight$135.00 ➝ $140.00
11/3/2020Leerink PartnersBoost TargetOutperform$150.00 ➝ $170.00
11/3/2020Robert W. BairdBoost TargetOutperform$130.00 ➝ $160.00
11/3/2020Bank of AmericaUpgradeNeutral ➝ Buy$125.00 ➝ $155.00
11/3/2020Piper SandlerBoost TargetOverweight$137.00 ➝ $147.00
11/3/2020OppenheimerUpgradeUnderperform ➝ Market Perform
9/22/2020JPMorgan Chase & Co.Initiated CoverageOverweight$148.00
9/18/2020Piper SandlerBoost TargetPositive ➝ Overweight$116.00 ➝ $137.00
9/10/2020Wells Fargo & CompanyBoost TargetOverweight$125.00 ➝ $135.00
9/9/2020Leerink PartnersBoost TargetPositive ➝ Outperform$120.00 ➝ $150.00
9/1/2020Robert W. BairdInitiated CoverageOutperform$130.00
8/21/2020Stifel NicolausBoost Target$110.00 ➝ $125.00
8/6/2020Wells Fargo & CompanyBoost TargetPositive ➝ Overweight$115.00 ➝ $125.00
8/6/2020Bank of AmericaDowngradeBuy ➝ Neutral$115.00
8/5/2020Piper SandlerBoost Target$98.00 ➝ $111.00
8/5/2020Leerink PartnersBoost TargetOutperform$110.00 ➝ $120.00
8/5/2020Lake Street CapitalBoost TargetBuy$100.00 ➝ $130.00
8/5/2020OppenheimerReiterated RatingSell$42.00 ➝ $50.00
7/15/2020The Goldman Sachs GroupInitiated CoverageBuy$148.00
6/29/2020Leerink PartnersBoost TargetOutperform$85.00 ➝ $110.00
6/18/2020Piper SandlerBoost TargetOverweight$81.00 ➝ $98.00
5/26/2020Wells Fargo & CompanyBoost TargetOverweight$81.00 ➝ $95.00
5/18/2020Lake Street CapitalInitiated CoverageBuy$90.00
5/6/2020GuggenheimBoost TargetBuy$80.00 ➝ $90.00
5/6/2020OppenheimerInitiated CoverageSell$42.00
4/28/2020Bank of AmericaUpgradeNeutral ➝ Buy$90.00
4/19/2020Piper SandlerInitiated CoverageOverweight$74.00
4/15/2020Stifel NicolausBoost TargetBuy$88.00 ➝ $95.00
4/9/2020Piper SandlerInitiated CoverageOverweight$74.00
4/2/2020OppenheimerLower Target$50.00 ➝ $42.00
2/26/2020Bank of AmericaBoost TargetNeutral$75.00 ➝ $85.00
2/26/2020Stifel NicolausBoost TargetBuy$82.00 ➝ $88.00
2/26/2020Leerink PartnersBoost TargetOutperform$75.00 ➝ $97.00
2/26/2020Wells Fargo & CompanyBoost TargetOverweight$90.00 ➝ $93.00
1/27/2020OppenheimerInitiated CoverageUnderperform$50.00
1/16/2020Wells Fargo & CompanyBoost TargetOverweight$70.00 ➝ $90.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.60 (Strong Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 32 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 21 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 17 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 34 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 27 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 21 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
10/21/2024
  • 38 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024
  • 42 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2024

Current Sentiment

  • 42 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Inspire Medical Systems logo
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
Read More

Today's Range

Now: $187.77
Low: $182.86
High: $191.60

50 Day Range

MA: $192.36
Low: $172.85
High: $211.63

52 Week Range

Now: $187.77
Low: $123.00
High: $257.40

Volume

876,574 shs

Average Volume

587,727 shs

Market Capitalization

$5.63 billion

P/E Ratio

175.49

Dividend Yield

N/A

Beta

1.31

Frequently Asked Questions

What sell-side analysts currently cover shares of Inspire Medical Systems?

The following Wall Street sell-side analysts have issued research reports on Inspire Medical Systems in the last twelve months: Bank of America Co., Jefferies Financial Group Inc., KeyCorp, Leerink Partners, Mizuho, Morgan Stanley, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, Truist Financial Co., and Wells Fargo & Company.
View the latest analyst ratings for INSP.

What is the current price target for Inspire Medical Systems?

0 Wall Street analysts have set twelve-month price targets for Inspire Medical Systems in the last year. Their average twelve-month price target is $233.58, suggesting a possible upside of 24.4%. Royal Bank of Canada has the highest price target set, predicting INSP will reach $260.00 in the next twelve months. Leerink Partners has the lowest price target set, forecasting a price of $197.00 for Inspire Medical Systems in the next year.
View the latest price targets for INSP.

What is the current consensus analyst rating for Inspire Medical Systems?

Inspire Medical Systems currently has 3 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for INSP.

What other companies compete with Inspire Medical Systems?

Other companies that are similar to Inspire Medical Systems include Zimmer Biomet, Solventum, Smith & Nephew, Penumbra and Glaukos. Learn More about companies similar to Inspire Medical Systems.

How do I contact Inspire Medical Systems' investor relations team?

Inspire Medical Systems' physical mailing address is 5500 WAYZATA BLVD SUITE 1600, GOLDEN VALLEY MN, 55416. The company's listed phone number is (844) 672-4357 and its investor relations email address is [email protected]. The official website for Inspire Medical Systems is www.inspiresleep.com. Learn More about contacing Inspire Medical Systems investor relations.